David Walter Pignolet
Chief Executive Officer at Juno Therapeutics GmbH
Profile
David Walter Pignolet is currently the Co-Managing Director at Celgene SRL (Belgium) since 2017, and also holds the position of Co-Managing Director at Juno Therapeutics GmbH and Director at Celgene Ltd.
He previously worked as Co-Managing Director at Celgene SAS.
David Walter Pignolet active positions
| Companies | Position | Start |
|---|---|---|
Juno Therapeutics GmbH
 Juno Therapeutics GmbH BiotechnologyHealth Technology Part of Bristol Myers Squibb Co., Juno Therapeutics GmbH is a German company that researches and develops cellular therapies. The company is based in Munich, Germany. The CEOs of the company are David Walter Pignolet, Lothar Germeroth. Juno Therapeutics was acquired by Juno Therapeutics, Inc., part of Bristol Myers Squibb Co. from March 07, 2018 on May 11, 2015 for $232.80 million. | Chief Executive Officer | - |
Celgene Ltd.
 Celgene Ltd. Pharmaceuticals: MajorHealth Technology Celgene Ltd. engages in the development of human pharmaceuticals and agrochemicals. It focuses on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. The company was founded on June 2, 2015 and is headquartered in Uxbridge, the United Kingdom. | Director/Board Member | 2019-02-19 |
Celgene SRL (Belgium)
 Celgene SRL (Belgium) Miscellaneous Commercial ServicesCommercial Services Part of Bristol Myers Squibb Co., Celgene SRL (Belgium) is a Belgian company that engages in research and development on biotechnology. The company is based in Watermaal-Bosvoorde, Belgium. The CEOs are Katherine Reynolds Kelly, David Walter Pignolet. The company was founded in 2006. | Chief Executive Officer | 2017-09-18 |
Former positions of David Walter Pignolet
| Companies | Position | End |
|---|---|---|
Celgene SAS
 Celgene SAS Pharmaceuticals: MajorHealth Technology Celgene SAS wholesales pharmaceutical products. Its products include Revlimid, vidaza, thalidomide, imnovid, Abraxane and Otezla. The company was founded in 1984 and is headquartered in Paris La Défense, France. | Chief Executive Officer | - |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
Juno Therapeutics GmbH
Juno Therapeutics GmbH BiotechnologyHealth Technology Part of Bristol Myers Squibb Co., Juno Therapeutics GmbH is a German company that researches and develops cellular therapies. The company is based in Munich, Germany. The CEOs of the company are David Walter Pignolet, Lothar Germeroth. Juno Therapeutics was acquired by Juno Therapeutics, Inc., part of Bristol Myers Squibb Co. from March 07, 2018 on May 11, 2015 for $232.80 million. | Health Technology |
Celgene Ltd.
Celgene Ltd. Pharmaceuticals: MajorHealth Technology Celgene Ltd. engages in the development of human pharmaceuticals and agrochemicals. It focuses on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. The company was founded on June 2, 2015 and is headquartered in Uxbridge, the United Kingdom. | Health Technology |
Celgene SAS
Celgene SAS Pharmaceuticals: MajorHealth Technology Celgene SAS wholesales pharmaceutical products. Its products include Revlimid, vidaza, thalidomide, imnovid, Abraxane and Otezla. The company was founded in 1984 and is headquartered in Paris La Défense, France. | Health Technology |
Celgene SRL (Belgium)
Celgene SRL (Belgium) Miscellaneous Commercial ServicesCommercial Services Part of Bristol Myers Squibb Co., Celgene SRL (Belgium) is a Belgian company that engages in research and development on biotechnology. The company is based in Watermaal-Bosvoorde, Belgium. The CEOs are Katherine Reynolds Kelly, David Walter Pignolet. The company was founded in 2006. | Commercial Services |
- Stock Market
- Insiders
- David Walter Pignolet
